PMID- 27029623
OWN - NLM
STAT- MEDLINE
DCOM- 20170206
LR  - 20220408
IS  - 1432-0843 (Electronic)
IS  - 0344-5704 (Linking)
VI  - 77
IP  - 5
DP  - 2016 May
TI  - Development of a skin rash within the first week and the therapeutic effect in 
      afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama 
      Lung Cancer Study Group experience.
PG  - 1005-9
LID - 10.1007/s00280-015-2910-9 [doi]
AB  - BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors 
      (EGFR-TKIs) are now key agents in treating EGFR-mutant non-small cell lung cancer 
      (NSCLC). The efficacy of gefitinib or erlotinib monotherapy can be predicted by 
      the development of a skin rash. However, it has not been fully evaluated if this 
      is the case with afatinib monotherapy. METHODS: We retrospectively studied 49 
      consecutive patients with EGFR-mutant NSCLC who received afatinib therapy between 
      2009 and 2015. The relationship of several toxicities with tumor response was 
      examined. RESULTS: Grade 2, or more severe, common adverse events (AEs) included 
      skin rash in 17 patients (35 %), diarrhea in 19 (39 %) and mucositis in 15 
      (31 %). Of these, the number of patients who developed >/=Grade 2 AEs during the 
      first week after the initiation of afatinib therapy was: five patients had skin 
      rash (10 %), 12 patients had diarrhea (25 %) and four patients had mucositis 
      (8 %). As for an objective response, 21 (43 %) of the 49 had a partial response. 
      Associating the AEs with the antitumor effect, those who had a >/=Grade 2 skin rash 
      within the first week tended to have a greater tumor response compared with those 
      without a rash (80 vs. 39 %; p = 0.077). CONCLUSION: Our small study demonstrated 
      that the early development of a skin rash might be associated with the response 
      to afatinib monotherapy.
FAU - Kudo, Kenichiro
AU  - Kudo K
AD  - Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
FAU - Hotta, Katsuyuki
AU  - Hotta K
AD  - Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan. 
      khotta@okayama-u.ac.jp.
AD  - Department of Hematology and Oncology, Okayama University Hospital, 2-5-1, 
      Shikatacho, Kitaku, Okayama, 700-8558, Japan. khotta@okayama-u.ac.jp.
FAU - Bessho, Akihiro
AU  - Bessho A
AD  - Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama, 
      Japan.
FAU - Nogami, Naoyuki
AU  - Nogami N
AD  - Department of Thoracic Oncology and Medicine, NHO Shikoku Cancer Center, 
      Matsuyama, Japan.
FAU - Kozuki, Toshiyuki
AU  - Kozuki T
AD  - Department of Thoracic Oncology and Medicine, NHO Shikoku Cancer Center, 
      Matsuyama, Japan.
FAU - Kuyama, Shoichi
AU  - Kuyama S
AD  - Department of Respiratory Medicine, NHO Iwakuni Medical Center, Iwakuni, Japan.
FAU - Inoue, Koji
AU  - Inoue K
AD  - Department of Respiratory Medicine, Ehime Prefectural Central Hospital, 
      Matsuyama, Japan.
FAU - Harita, Shingo
AU  - Harita S
AD  - Department of Respiratory Medicine, Chugoku Central Hospital, Fukuyama, Japan.
FAU - Okada, Toshiaki
AU  - Okada T
AD  - Department of Respiratory Medicine, Chugoku Central Hospital, Fukuyama, Japan.
FAU - Gemba, Kenichi
AU  - Gemba K
AD  - Department of Respiratory Medicine, NHO Fukuyama Medical Center, Fukuyama, Japan.
FAU - Fujii, Masanori
AU  - Fujii M
AD  - Department of Respiratory Medicine, Japanese Red Cross Kobe Hospital, Kobe, 
      Japan.
FAU - Takigawa, Nagio
AU  - Takigawa N
AD  - Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, 
      Japan.
FAU - Oda, Naohiro
AU  - Oda N
AD  - Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
FAU - Tanimoto, Mitsune
AU  - Tanimoto M
AD  - Department of Hematology and Oncology, Okayama University Hospital, 2-5-1, 
      Shikatacho, Kitaku, Okayama, 700-8558, Japan.
FAU - Kiura, Katsuyuki
AU  - Kiura K
AD  - Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160331
PL  - Germany
TA  - Cancer Chemother Pharmacol
JT  - Cancer chemotherapy and pharmacology
JID - 7806519
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Quinazolines)
RN  - 41UD74L59M (Afatinib)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Adult
MH  - Afatinib
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/administration & dosage/*adverse effects/therapeutic use
MH  - Cancer Care Facilities
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics/metabolism
MH  - ErbB Receptors/*genetics
MH  - Exanthema/*chemically induced
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/genetics/metabolism
MH  - Male
MH  - Middle Aged
MH  - Mutation
MH  - Quinazolines/administration & dosage/*adverse effects/therapeutic use
MH  - Retrospective Studies
MH  - Time Factors
OTO - NOTNLM
OT  - Afatinib
OT  - Lung cancer
OT  - Response
OT  - Skin rash
EDAT- 2016/04/01 06:00
MHDA- 2017/02/07 06:00
CRDT- 2016/04/01 06:00
PHST- 2015/08/31 00:00 [received]
PHST- 2015/11/05 00:00 [accepted]
PHST- 2016/04/01 06:00 [entrez]
PHST- 2016/04/01 06:00 [pubmed]
PHST- 2017/02/07 06:00 [medline]
AID - 10.1007/s00280-015-2910-9 [pii]
AID - 10.1007/s00280-015-2910-9 [doi]
PST - ppublish
SO  - Cancer Chemother Pharmacol. 2016 May;77(5):1005-9. doi: 
      10.1007/s00280-015-2910-9. Epub 2016 Mar 31.